AcquisitionsJun 12, 2026, 04:22 PM
Centessa Pharmaceuticals Shareholders Approve Eli Lilly Acquisition
AI Summary
Centessa Pharmaceuticals plc shareholders approved the previously announced acquisition by LDH XV Corporation, a subsidiary of Eli Lilly and Company, through a court-sanctioned scheme of arrangement. All resolutions related to the acquisition were duly passed at both the Scheme Meeting and the Company General Meeting. Additionally, the company held its 2026 Annual General Meeting, where all matters submitted to a vote, including the re-appointment of directors and auditors, were approved.
Key Highlights
- Centessa shareholders approved the Eli Lilly acquisition scheme with 126,653,456 votes for and 23,007 against.
- The Company Shareholder Resolution for the scheme was approved with 126,658,949 votes for.
- All resolutions at the Annual General Meeting were approved, establishing a quorum with 134,569,251 shares.
- Carol Stuckley was re-appointed as director with 123,881,793 votes for.
- Brett Zbar was re-appointed as director with 122,561,168 votes for.
- Mathias Hukkelhoven was re-appointed as director with 105,704,743 votes for.
- KPMG LLP was re-appointed as UK statutory auditors.
Price Impact
More from CNTA